Methodologies for in silico and in vitro Test of Biphenylalanine Compounds as Potential HIV-1 gp120 Attachment Inhibitors
Abstract
We postulate that biphenylalanine and its derivatives are propitious candidates to inhibit the binding of HIV-gp120 to CD4 T-cell. Many biphenylalanine derivatives are synthesized chemically and also prevailing in nature. We have proposed atom- and bond-based 2D TOMOCOMD-CARDD approach to identify the best derivative. Moreover, according to our proposition, the principal law simulated from in silico interaction of gp120 with CD4 can be tested by ELISA in vitro. Furthermore, the toxicity of biphenylalanine compounds might be evaluated using MTT cytotoxicity test kits for future development of attachment inhibitors in vivo. It will be a novel idea to determine the efficacy of biphenylalanine compounds as a drug. To determine, in advance the possible stable mutation forms (all mutations are not stable) around the apolar ‘Phe43 cavity’ on gp120 and predict the next generation drugs against these mutations we opine to develop a discriminated function of local (amino acid-type) linear indices of the “macromolecular pseudograph’s α-carbon atom adjacency matrix”- that permits the classification of mutants as near wild type stability or reduced stability. To sum up, the consummate biphenylalanine substances will likely to be an ace in a hole for millions of people worldwide.
Keywords: Biphenylalanine compounds, HIV-1 gp120, CD4 T-cell, HIV
Cite this Article
Al-Mujahidy SK. Md. Jakaria. Methodologies for in silico and in vitro test of biphenylalanine compounds as potential HIV-1 gp120 attachment inhibitors. Research & Reviews: A Journal of Bioinformatics. 2015; 2(3): 38–42p.
Downloads
Published
Issue
Section
License
Copyright Transfer and Declaration Form (Please compile this form, sign and send by e-mail and post)
Journal Title:
Title of the Paper:
Corresponding Author’s Information:
Name:
Address:
E-mail:
Contact Number:
It is herein agreed that:
The copyright to the above-listed unpublished and original article is transferred to STM Journals. This copyright transfer covers the exclusive right to reproduce and distribute the contribution, including reprints, translations, photographic reproductions, microform, electronic form (offline, online), or any other reproductions of similar nature. I/We declare that above manuscript is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere. I/ We warrant(s) that his/her/their contribution is original, except for such excerpts from copyrighted works as may be included with the permission of the copyright holder and author thereof, that it contains no libelous statements, and does not infringe on any copyright, trademark, patent, statutory right, or propriety right of others. I/We will not publish his/her/their above said contribution anywhere else without the prior written permission of the publisher unless it has been changed substantially.
I/We also agree to the authorship of the article in the following order:
Author(s) Name Signature(s)
1. ________________
2. ________________
3. ________________
4. ________________
The author(s) agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal (comments if any to the editor can be added below).
